Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SVT-23473
- Development stage
- Preclinical
- Lead developer
- Laboratorios Salvat
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
SVT-23473 is an investigational ophthalmic nanoemulsion being developed by Laboratorios Salvat for the treatment of episodic dry eye disease. The drug utilizes Salvat's proprietary IMPACT-SVT® nanoemulsion drug delivery technology, which is designed to improve drug penetration and bio-adhesion to the ocular surface while providing enhanced comfort. The formulation is presented in single-dose, preservative-free containers for topical ophthalmic administration. It is currently in the development stage, aiming to address the symptoms of dry eye syndromes through improved ocular surface hydration or delivery of an undisclosed active agent.
Beyond the preview
Go deeper on SVT-23473.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SVT-23473.